[IE-02-5] Combination antithrombotic regimens for secondary stroke prevention
Karen Furie, MD, MPH is Chief of Neurology at Rhode Island Hospital, The Miriam Hospital and Bradley Hospital, and serves as Professor and Chair of the Department of Neurology at The Warren Alpert Medical School of Brown University and co-director of the Norman Prince Neurosciences Institute. She was the principal investigator of the NINDS P50 Partners Specialized Program of Translational Research in Acute Stroke (SPOTRIAS) and the American Heart Association supported Harvard Bugher Center for Stroke Prevention and Genetics Research while at MGH. Dr. Furie has been involved in organizing and executing clinical trials dating back to the Trial or Org 10172 in acute stroke (TOAST). She was a co-investigator in the Enlimomab, CAPRIE, WARSS, VISP, WARCEF, MATCH, PRoFESS, and IRIS trials. In addition, Dr. Furie served as Chair of the NSDK and ANIE study sections, co-Chair of NST-1 and on the DSMB’s of WASID, SPS3, ARUBA, StrokeNet, CREST-2, and SIREN. Dr. Furie’s interest in biomarkers is broad. She has studied vitamins and homocysteine, inflammatory biomarkers, markers of oxidative stress and coagulation, genetics/genomics, and multimodal imaging. Currently, Dr. Furie is a co-PI on the SPIRIT StrokeNet superhub.
抄録パスワード認証
第65回日本神経学会学術大会プログラム・抄録集の19ページに記載しています。